Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A project led by Professor Hugh Watkins at the Radcliffe Department of Medicine is one of the four projects on the shortlist of four research projects competing for a single £30 million award from the British Heart Foundation.

© Credit: University of Oxford, Dr P.Hales/BBSRC

The charity says it is one of many radical new approaches needed to address a frightening mismatch in research funding compared with the burden of heart and circulatory diseases.

With the World Health Organization forecasting an increase in cardiovascular deaths worldwide, the charity’s Big Beat Challenge is a global initiative to galvanise researchers and inspire transformational solutions to tackle the world’s biggest killer.

Professor Watkins' project aims to develop a cure for genetic heart muscle diseases which affect about 160,000 people in the UK, and about one million in the US. These cardiomyopathies affect the heart muscle, and are the leading cause of sudden cardiac death and heart failure in young people. While treatments to manage the symptoms of the disease exist, there is no cure for the root cause. 

Read more on the Radcliffe Department of Medicine website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.